The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The new assay consolidates screening for four major viral threats into a single workflow
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The decision is based on the phase 3 DESTINY-Breast11 trial
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Subscribe To Our Newsletter & Stay Updated
